

INTROGEN THERAPEUTICS INC

Form 8-K

May 30, 2006

Table of Contents

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**FORM 8-K
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): May 30, 2006 (May 23, 2006)

Introgen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation)

0-21291

(Commission File Number)

74-2704230

(IRS Employer
Identification No.)

**301 Congress Avenue, Suite 1850
Austin, Texas 78701**

(Address of principal executive offices, including zip code)

(512) 708-9310

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 1.01. Entry into a Material Definitive Agreement.

Item 9.01. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT INDEX

Form of Stock Purchase Agreement

Table of Contents

Item 1.01. Entry into a Material Definitive Agreement.

On May 23, 2006, the Compensation Committee (the Committee) of the Board of Directors of Introgen Therapeutics, Inc. (the Company) awarded 7,500 shares of the Company's common stock (the Shares) to each of the Company's directors, other than David G. Nance, and a cash payment of \$11,600.00 to each of the Company's directors.

Pursuant to a form of stock purchase agreement, a copy of which is attached hereto as Exhibit 10.56, the Company issued the Shares to each of William H. Cunningham, Ph.D., S. Malcolm Gillis, Ph.D., Peter Barton Hutt, John N. Kapoor, Ph.D. and Charles E. Long at a per Share purchase price of \$4.64, which purchase price for the Shares has been paid by each such director via services previously rendered to the Company.

The Shares were issued from the Company's 2000 Stock Option Plan and must be held by each director until the earlier of (i) the Committee approves any disposition of the Shares, or of any beneficial interest therein, by such director prior to such disposition or (ii) the director is no longer a service provider to the Company and (a) such disposition is executed more than six months after any opposite transaction subject to Section 16(b) of the Securities Exchange Act of 1934, as amended, that occurred while the director was a director or officer of the Company or (b) is otherwise exempted under Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to the rules promulgated thereunder.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No. Description

10.56 Form of Stock Purchase Agreement

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTROGEN THERAPEUTICS, INC.

By: /s/ James W. Albrecht, Jr.
James W. Albrecht, Jr.
Chief Financial Officer

Date: May 25, 2006

Table of Contents

EXHIBIT INDEX

Exhibit No.	Description
10.56	Form of Stock Purchase Agreement